Bryan J. Fraser

Bryan J. Fraser

Auto-generated profile, based on publicly available information

Bryan J. Fraser

Structural Genomics Consortium Toronto

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BFBryan J. Fraser
Bryan J. Fraser
RWRyan P. Wilson
Ryan P. Wilson
SFSára Ferková
Sára Ferková
OIOlzhas Ilyassov
Olzhas Ilyassov
JLJackie Lac
Jackie Lac
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We show these proteases spontaneously and efficiently cleave their own zymogen activation motifs, activating their broader protease activity on cellular substrates. We determine TMPRSS11D co-crystal structures with a native and an engineered activation motif, revealing insights into its autocleavage activation and distinct substrate binding cleft features. Leveraging this structural data, we develop nanomolar potency peptidomimetic inhibitors of TMPRSS11D and TMPRSS2. We show that a broad serine protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. In this work, we develop mechanistic insights into human protease viral tropism and highlight both the strengths and limitations of existing human serine protease inhibitors, informing future drug discovery efforts targeting these proteases.

31 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GLGabriel Lemieux
Gabriel Lemieux
JPJimena Pérez-Vargas
Jimena Pérez-Vargas
ADAntoine Désilets
Antoine Désilets
MHMalihe Hassanzadeh
Malihe Hassanzadeh
CTConnor A. H. Thompson
Connor A. H. Thompson
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
The worldwide spread of new SARS-CoV-2 variants emphasizes the need to diversify existing therapeutic strategies. TMPRSS2, a host protease crucial for SARS-CoV-2 entry, has garnered significant research attention as a potential target for therapeutic intervention. Here, we optimized N-0385, a previously reported TMPRSS2 ketobenzothiazole-based peptidomimetic inhibitor, by screening 135 derivatives for target affinity and antiviral potency. Among the top candidates, N-0695 exhibited low nanomolar Ki values against three TTSPs associated with respiratory virus entry: TMPRSS2, matriptase, and TMPRSS13. Notably, N-0920 demonstrated exceptional potency in reducing SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, representing the first in cellulo picomolar inhibitor with EC50 values of 300 and 90 pM, respectively. Additionally, molecular modeling provided insights into the binding interactions between the compounds and their targets. This study underscores the effectiveness of our screening approach in refining an existing peptidomimetic scaffold to enhance selectivity and antiviral activity.

19 September 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BFBryan J. Fraser
Bryan J. Fraser
NYNicholas J. Young
Nicholas J. Young
BBBrian J. Bender
Brian J. Bender
SGStefan Gahbauer
Stefan Gahbauer
OIOlzhas Ilyassov
Olzhas Ilyassov
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Transmembrane protease serine-2 (TMPRSS2) is an essential host entry factor in human airways for SARS-CoV-2 and influenza A/B and has presented as a target for antiviral drug development; however, no clinically viable oral small-molecule TMPRSS2 inhibitors have been developed to date. Here, we perform two large-scale docking campaigns to identify covalent and noncovalent TMPRSS2 small-molecule inhibitors using a homology model and crystal structure. We establish a pipeline to rapidly screen TMPRSS2 inhibitors and then interrogate the potency, selectivity, and biophysical properties of covalent and noncovalent inhibition using enzyme kinetics on synthetic peptide and protein substrates and differential scanning fluorimetry. Furthermore, we established a readily crystallizable form of TMPRSS2 protein that produced high-resolution crystal structures with nafamostat, ‘157, and 6-amidino-2-naphthol. A novel noncovalent inhibitor scaffold is biochemically validated as a potential avenue for developing TMPRSS2-selective inhibitors.

9 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BFBryan J. Fraser
Bryan J. Fraser
RWRyan P. Wilson
Ryan P. Wilson
OIOlzhas Ilyassov
Olzhas Ilyassov
JLJackie Lac
Jackie Lac
ADAiping Dong
Aiping Dong
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We demonstrate these proteases can spontaneously and efficiently cleave their own zymogen activation motifs, thereby activating their wider protease activity on other cellular substrates. We determined TMPRSS11D co-crystal structures in complexes with a native TMPRSS11D zymogen activation motif and with an engineered activation motif, providing insights into TMPRSS11D autocleavage activation and revealing unique regions of its substrate binding cleft. We further show that a protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. These insights into human protease viral tropism and into liabilities with existing human serine protease inhibition strategies will guide future drug discovery campaigns for these targets.

18 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
BFBryan Fraser
Bryan Fraser
NYNicholas Young
Nicholas Young
BBBrian Bender
Brian Bender
SGStefan Gahbauer
Stefan Gahbauer
OIOlzhas Ilyassov
Olzhas Ilyassov
CACheryl Arrowsmith
Cheryl Arrowsmith
Transmembrane protease, serine -2 (TMPRSS2) is an essential host entry factor in human airways for SARS-CoV-2 and influenza A/B and has presented as a target for antiviral drug development; however, no clinically viable, oral small molecule TMPRSS2 inhibitors have been developed to date. Here we perform two large-scale docking campaigns to identify covalent and noncovalent TMPRSS2 small molecule inhibitors from a homology model and crystal structure. We establish a pipeline to rapidly screen TMPRSS2 inhibitors, then interrogate the potency, specificity and biophysical properties of covalent and noncovalent inhibition using enzyme kinetics on synthetic peptide and protein substrates and differential scanning fluorimetry. Furthermore, we established a readily crystallizable form of TMPRSS2 protein that produced high resolution crystal structures with nafamostat, ‘157, and 6-amidino-2-naphthol. A novel noncovalent inhibitor scaffold is biochemically and biophysically validated as a potential avenue to develop TMPRSS2-selective inhibitors.

12 August 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BFBryan J. Fraser
Bryan J. Fraser
RWRyan P. Wilson
Ryan P. Wilson
JLJackie Lac
Jackie Lac
OIOlzhas Ilyassov
Olzhas Ilyassov
ASAlmagul Seitova
Almagul Seitova
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith